Novartis AG (NVS)

93.56
0.70 0.74
NYSE : Health Technology
Prev Close 94.26
Open 94.80
Day Low/High 93.37 / 94.87
52 Wk Low/High 74.97 / 96.31
Volume 3.48M
Avg Volume 2.21M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 236.72B
EPS 5.50
P/E Ratio 17.52
Div & Yield 1.84 (2.04%)
Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.

Novartis In Talks to Buy Generic Drug Maker

Novartis In Talks to Buy Generic Drug Maker

Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Novartis Shares Slip Tuesday on Falling Profit

Novartis Shares Slip Tuesday on Falling Profit

Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.

X(encor) Marks the Spot For Potential Gains

X(encor) Marks the Spot For Potential Gains

You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

Novartis downgraded at Leerink

Valeant Looks Like a Choirboy Next to Mallinckrodt, Says Andrew Left

Valeant may have troubles, but Mallinckrodt is the poster child of price gouging.

3 Pharma Stocks to Heal Your Portfolio

Dividend yield is the determining factor in this strategy.

U.S. Futures Down as Oil Erases Gains; Fed Statement Expected Today

U.S. futures are down ahead of the final day of the Fed's 2-day policy meeting on Wednesday. 

As the World Economic Forum Starts in Davos, Watch These 3 Swiss Stocks

The WEF host country has a lot to offer to investors.

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Small biotech plunged in July, but has stabilized on two key deals.

Schlumberger, Lowe’s Shares Heading Higher Says Edward Jones Strategist

Schlumberger, Lowe’s Shares Heading Higher Says Edward Jones Strategist

Underlying support for stock prices remains positive, especially if oil prices stabilize near current levels and the dollar does not rise a lot further.

J&J, Eli Lilly Healthy for Your Portfolio Says Causeway Global Manager

J&J, Eli Lilly Healthy for Your Portfolio Says Causeway Global Manager

Healthcare stocks were hit hard in the third quarter after leading the S&P 500 for the first half of the year.

Global Stocks Fall After the Federal Reserve Keeps Rates at Record Low

And four other things you need to know now.

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.

Quant Picks: 4 Pharmaceutical Companies to Add to Your Porfolio

Quant Picks: 4 Pharmaceutical Companies to Add to Your Porfolio

Here are some of the best pharmaceuticals our algorithm says you should consider looking at.

Quant Picks: 3 Pharmaceutical Companies That Pay High Dividends

Quant Picks: 3 Pharmaceutical Companies That Pay High Dividends

Here are some of the best pharmaceutical companies, that pay high dividends, TheStreet Quant Ratings says you should consider looking at.

European Markets Gain as Greece Faces Sunday Debt-Deal Ultimatum

European Markets Gain as Greece Faces Sunday Debt-Deal Ultimatum

European markets rose Wednesday after European leaders gave Greece a Sunday ultimatum for a final rescue deal or face eviction from the single currency.

What's So Great About an Up Opening?

Don't rely on Europe; it's too out of sync with U.S.

You Have to Love Biotech

In this era of turmoil, investors can take comfort in this sector.

Merger Mania Benefits Mylan

Merger Mania Benefits Mylan

Whether it's acquiring or the acquired, Mylan is building shareholder value.

Rules of the Game: Portfolio Review Time

Let's take a little tour through the various equity asset classes.

Profit From the Longer Life Spans, Part 1

Profit From the Longer Life Spans, Part 1

Americans are living much longer these days -- and there are a number of ways to invest.

Riding the Coattails of Mega-Caps

A selection based on James P. O'Shaughnessy's strategy.

Budweiser and Gerber Among Larger U.S. Brands Overseas

Budweiser and Gerber Among Larger U.S. Brands Overseas

Some of the most well-known American brands aren't actually so American, after all.

What to Watch Monday, May 5: Earnings From Drug Giant Pfizer

What to Watch Monday, May 5: Earnings From Drug Giant Pfizer

Investors will be tracking Pfizer's earnings when they report first-quarter results on May 5. Expectations are for earnings of $0.55 a share on sales of $12.07 billion.